ADC Therapeutics SA

NYSE:ADCT

1.96 (USD) • At close December 20, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2023202220212020201920182017
Revenue 69.558209.90833.91702.341.141.803
Cost of Revenue 2.5294.5791.3931.972107.537118.08685.53
Gross Profit 67.029205.32932.524-1.972-105.197-116.946-83.727
Gross Profit Ratio 0.9640.9780.9590-44.956-102.584-46.438
Reseach & Development Expenses 127.127187.898158.002142.032107.537118.31385.53
General & Administrative Expenses 48.424141.05871.46277.23113.8148.6027.806
Selling & Marketing Expenses 57.46469.05264.7822.101000
SG&A 105.888141.058136.24277.23113.8148.6027.806
Other Expenses 014.57828.489-46.3980.3880.1660.137
Operating Expenses 233.015328.956294.244219.263121.739127.08193.473
Operating Income -165.986-123.627-261.72-219.263-119.399-125.941-91.67
Operating Income Ratio -2.386-0.589-7.7160-51.025-110.475-50.843
Total Other Income Expenses Net -29.433-33.55710.215-26.73.4973.0691.856
Income Before Tax -195.419-154.661-251.505-245.963-115.902-122.872-89.814
Income Before Tax Ratio -2.809-0.737-7.4150-49.531-107.782-49.814
Income Tax Expense 39.1061.139-21.4790.3270.5820.2240.048
Net Income -240.053-155.8-230.026-246.29-116.484-123.096-89.862
Net Income Ratio -3.451-0.742-6.7820-49.779-107.979-49.84
EPS -2.94-1.99-3-3.77-1.74-2.29-1.53
EPS Diluted -2.94-1.99-3-3.77-1.74-2.29-1.53
EBITDA -146.762-108.055-223.715-219.263-114.1-122.359-91.329
EBITDA Ratio -2.11-0.471-6.8750-48.652-110.012-51.111